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1. Introduction 
Neurodegenerative diseases are progressive, hereditary or sporadic diseases of the nervous 
system. Progressive neurodegeneration causes i.e. loss of movement ability like in motor 
neuron diseases or cognitive deficits like in dementia. Despite the fact that many similarities 
appear on the sub-cellular level that relate different neurodegenerative diseases with each 
other, the broad variety on the clinical level remains which causes major demands both in 
clinical care and daily living.  
Advances in neuroimaging have led to an extensive application of this technique in clinical 
and scientific studies. Neuroimaging is a non-invasive approach of measuring either 
structural properties or activity of the brain. Activity of the brain can be investigated during 
defined tasks or during rest to observe functional connectivity of cortical and subcortical 
regions in time and space. Neuroimaging in neurodegenerative diseases has extensively 
increased our understanding of interaction of functional executive decline e.g. in movement 
and cognition and of changes in cortical pattern activity. Neuroimaging is a promising 
candidate for an objective marker for e.g. drug efficacy. By these means, neuroimaging as a 
biomarker can improve predictability of outcome in clinical trials. Furthermore, discovering 
patterns of vulnerability of neurons on the cortical and subcortical level helps to disentangle 
the course of degeneration in different diseases in vivo to support post-mortem findings. 
Those ex-vivo analyses had been the only means to get an understanding of disease courses 
before neuroimaging evolved. 
The following article will give an introduction to the characteristics of the main 
neurodegenerative diseases and techniques that have been used in understanding 
pathogenesis and aetiology of neurodegenerative diseases. It encompasses main findings in 
structural and functional neuroimaging in Motor Neuron Diseases (MND) and in others like 
dementias, Parkinson’s disease (PD) and Huntington’s disease. 
With our work we mainly focused on Motor Neuron Diseases like ALS and we provided 
clear evidence for pathological involvement of areas extending the motor system like 
emotional and sensory processing pathways. Overall, the article will highlight the capacity 
of neuroimaging to shed light onto aetiology and pathogenesis of neurodegeneration in the 
human central nervous system. 
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2. Clinical understanding and differential diagnosis among 
neurodegenerative diseases 
Neurodegenerative diseases encompass different pathologies with the common feature of 
progressive loss of structure or function of neurons. 
Over the last years, evidence evolved of common pathological processes in different 
neurodegenerative diseases like accumulation of neurofilaments, protein degradation and 
induced cell death. For example, accumulated TDP-43 is found in sporadic ALS cases, which 
links this disease to fronto-temporal dementias (FTD) (Neumann et al., 2006). Furthermore, 
on behavioural level there is accumulating evidence for a common cognitive decline in some 
ALS patients and in patients with FTD. 
Genetics provide further evidence for an association between different neurodegenerative 
diseases like polyglutamine repeats in Huntington’s disease and spinocerebellar ataxias and 
mutations in the alpha-synuclein in Parkinson’s Disease, dementia with Lewy bodies and 
multiple system atrophy. Furthermore, mitochondrial dysfunction, disturbed axonal 
transport and endothelial dysfunction are common pathological hallmarks found in 
different neurodegenerative diseases. In clinical routine, differential diagnosis is usually 
done on clinical basis. According to clinical criteria, Amyotrophic lateral sclerosis is 
regarded as a disease of the peripheral and central nervous system and the other most 
common neurodegenerative diseases like dementias, Parkinson’s disease and Huntington’s 
disease are primarily regarded as diseases of the central nervous system (Hacke, 2007). 
However, evidence for overlaps in molecular or cellular pathways question this 
classification and suggests a major overlap of different neurodegenerative pathologies in 
central and peripheral nervous system (Braak et al., 2006b; Braak & Del Tredici, 2011a, 
2011b; Grammas et al., 2011; Neumann et al., 2006). New imaging techniques carry the hope 
of revolutionizing the diagnosis of neurodegenerative disease to improve staging of patients 
and follow disease progression and treatment trial efficacy. 
3. Characteristics of main neurodegenerative diseases 
3.1 Diseases of the central and peripheral nervous system and muscles 
3.1.1 Motor Neuron Diseases (MND) 
Motor neuron diseases describe pathologies of the motor system. The most common is 
Amyotrophic Lateral Sclerosis, which evolves mostly in midlife and is characterised by a 
fast progression of immobility and loss of verbal communication. Cognition is mostly 
unaffected; yet, there is an on-going debate on the proportion of patients with cognitive 
impairments. There are more benign forms of motor degenerative diseases e.g. affecting just 
the upper or just the lower motor neurons (Ludolph and Dengler, 1999). ALS, which affects 
upper and lower motor neurons, is usually fast progressing causing death within 3-5 years. 
The fatal event is usually respiratory failure. There is a gender ratio of men: women of about 
1.5: 1. 
The cause of ALS is mostly unknown. In the early 1990s there was evidence provided that 
some patients with a familial form of ALS have a defined mutation in the Superoxide-
Dismutase 1 (SOD1). Since then various genetic changes have been detected as a possible 
cause for ALS. However, for most cases the cause is yet unknown. Riluzole as a glutamate 
agonist is the only applicable drug in ALS that prolongs life of ALS patients. Numerous 
drug trials are ongoing to provide new therapeutic targets in ALS. 
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3.2 Disease of the central nervous system 
3.2.1 Dementias 
Alzheimer’s disease (AD) is the most common form of dementia. It is named after the 
German psychiatrist and neuropathologist Alois Alzheimer who first described the disease 
in the early 20th century. The other most common form of dementia is vascular dementia. 
Some other forms are dementia with Lewy bodies, and frontotemporal lobal degeneration, 
which is subdivided into the behavioural variant (fronto-temporal dementia, FTD), the 
semantic dementia, primary progredient aphasia, corticobasal degeneration, progressive 
supranuclear palsy and amyotrophic lateral sclerosis with frontotemporal dementia. 
Numerous other neurodegenerative illnesses have an associated dementia, including 
Creutzfeldt–Jakob disease, Huntington’s disease, multiple system atrophy, and Parkinson’s 
disease dementia (Tartaglia et al.,2011). 
dementias are acquired diseases that clinically affect cognitive abilities and daily activities. 
Classification of dementias can be done according to different criteria: cortical (memory, 
language, thinking and social skills are affected) and subcortical pathology (emotional 
processing, movement and memory are primarily affected). Furthermore, it can be classified 
according to whether it is a progressive form (cognitive abilities worsen over time), and 
whether it is primary (results from a specific disease such as Alzheimer's disease) or 
secondary (occurs because of disease or injury like vascular dementia). Patho-anatomical 
hallmark is the degeneration of the brain (mainly frontal and temporal areas). Early stages 
of dementia are often mistakenly considered as normal aging problems like forgetfulness 
and memory storage problems. With the means of standardised diagnostic tools problems in 
memory, language (aphasia), attention, planning and concept formation, psychomotor 
function and personality problems can be detected. 
Due to the changing demographics in western countries, the incidence of dementias 
constantly increases. About 5-10% of the people >65 years and 30-40% of those above 80 
develop dementias. Incidence increases exponentially with age. Women are more often 
affected than men.  
The cause of Alzheimer’s disease is not fully understood. There are several hypotheses, 
which have different supporters. The most widely used hypothesis is the amyloid 
hypothesis. Amyloid beta deposits are found in the brain of AD patients preceding the onset 
of clinical dementia. However, amyloid beta is not pathological per se and is found in 
healthy aged people. Furthermore, amyloid plaque deposition do not correlate with neuron 
loss and also not with clinical symptoms. Abnormally phosphorylated tau protein may start 
quite early, i.e., before puberty or in early young adulthood and therefore decades before 
clinical onset of the disease (Braak & Del Tredici, 2011b).  
3.2.2 Parkinson’s Disease (PD) 
Parkinson’s disease is the second most common degenerative disease of the central nervous 
system. Pathological hallmark of the idiopathic Parkinson’s syndrome are movement related 
symptoms like slowness of movements, rigidity and tremor. Subtypes distinguish between 
the predominance of symptoms in a patient. Changes in mood and cognitive deficits are 
described as non-motor symptoms in PD. In late stage PD dementia is a common hallmark. 
Like ALS, PD affects people in midlife. However, there is evidence that disease process 
starts early in life (Braak & Del Tredici 2011b). The disease is caused by death of 
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dopaminergic cells in substantia nigra of the midbrain that project to the striatum. The 
pathological process of PD (formation of proteinaceous intraneuronal Lewy bodies and 
Lewy neurites) begins at two sites and continues in a topographically predictable sequence 
in six stages, during which components of the olfactory, autonomic, limbic, and 
somatomotor systems become progressively involved (Braak et al., 2006a). PD cannot be 
cured but dopaminergic medication is an effective treatment for the disease. However, 
medication may become ineffective in the cause of disease. Deep brain stimulation is an 
available tool in PD if no other therapy is applicable. 
3.2.3 Huntington’s Disease 
Huntington’s disease (HD) is a movement disorder with inability to control movements: 
involuntary, sudden, fast and erratic movements of distal extremities, face, neck and trunk 
are seen. In early stages of HD slightly exaggerated movements might be considered as 
nervousness, however, in the course of the disease control of coordinated body movements 
are becoming more and more difficult, especially affecting walking. Men and women are 
similarly affected. Disease onset is usually between 30 and 50 years. 
Huntington described the disease already in 1872. It has a prevalence of 2-10 per 100 000 
inhabitants. It is an autosomal dominant genetic cause with full penetrance. There is a 50% 
chance of diseased offspring and therefore presymptomatic enrolment in clinical trials is 
possible. 
4. Common neuroimaging techniques  
Neuroimaging techniques in degenerative diseases are used to investigate structural or 
functional changes in the brain and spinal chord. Those techniques may be used to support 
clinical diagnosis or, as for most of the functional techniques, are used in research to enrich 
our understanding of pathophysiological outcomes of neurodegenerative processes. 
4.1 Structural techniques 
4.1.1 Anatomical scans with CT and MRI 
Conventional radiography like computerized tomography (CT) is still widely used in 
traumatology and other fields of medicine. For CT, x-rays pass through the body and are 
attenuated in the tissue. The denser a tissue is, the more the x-rays are attenuated. Detectors 
pick up the signals and digital geometry processing generates three-dimensional images of 
e.g. the brain. CT has mainly lost its importance in the clinical evaluation of 
neurodegenerative diseases. 
With the finding of magnetic resonance imaging (MRI) in the 1970s, a new era of medical 
neuroimaging evolved to visualize structures of the central nervous system. MRI uses the 
property of magnetic resonance in atoms with uneven number of nuclei. In living 
organisms, protons are mostly used, but any other atom with the according properties can 
similarly be used. An object (e.g. a human) is placed within a permanent magnetic field. A 
proportion of the protons align within this field. Gradient pulses in a high radio frequency 
are pulsed to deflect the spins of the protons. Inbetween those pulsed gradients, spins return 
to their original position and emit energy. This emission can be detected in MRI.  
MRI images provide images of soft tissue e.g. the brain with high contrasts and without 
bone artefacts. Therefore, MRI is applicable to visualize anatomical and pathological 
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structures in the scull and in the spinal canal. Furthermore, in functional MRI it is applicable 
to non-invasively visualise brain function in vivo. 
4.1.2 Spectroscopy 
Whereas MRI gives only information about the structure of the body like the distribution of 
water and fat, magnetic resonance spectroscopy is suitable to give information of property 
and chemical structure of tissue. MRS provides information on the nuclei of atoms, which 
allows deduction on the chemical properties of a tissue.  It is a non-invasive technique, 
which is used in some clinical fields like tumour diagnostic. It can as well provide evidence 
of longitudinal change in cerebral function using proton-based metabolites (among others 
choline, creatine, lactate, N-acetylaspartate (NAA), glutamate). NAA is thought to be a 
marker of neuronal integrity and is therefore used as a diagnostic marker in 
neurodegenerative diseases. MRS has been used in research but fields of clinical application 
are expanding i.e. longitudinal change of metabolites in therapeutic intervention (Turner et 
al., 2011).  
4.1.3 Voxel based morphometry MRI 
Voxel based morphometry (VBM) in MRI quantifies white or gray matter volume in the 
CNS. It is a non-invasive technique to detect brain volume changes in vivo and compare it 
between groups e.g. patients with neurodegenerative diseases and healthies. VBM registers 
every brain to a brain template to provide for main anatomical differences between brains. 
Statistical comparison of each subvolume of the brain (so called voxels) allows fast 
quantification of brain volume alterations.  
4.1.4 Diffusion tensor imaging 
Diffusion tensor imaging (DTI) is based on the physics of diffusion of all molecules in e.g. 
the human body according to Brownian motion theory. Membranes, fibres and other 
molecules restrict the movement of molecules and the molecules align along barriers. The 
stronger the aligned diffusion, the higher is the anisotropy. In living tissue, fractional 
anisotropy (FA) is at its minimum (0) where there are no barriers and diffusion is not 
directed. FA is at its maximum (1) if alignment of diffusion is highest. DTI is applicable in 
white matter pathology in neurodegenerative diseases. DTI based fibre tracking gives 
additional information on directionality and can therefore be used to visualise e.g. direction 
and strength of bundles of white matter fibres within the brain.  In neurodegenerative 
diseases it’s applicable to detect white and grey matter loss. 
4.2 Functional neuroimaging 
Functional neuroimaging in neurodegenerative disease aims to explore the functional state 
of the brain as well as the capacity of the adult brain to functionally compensate for 
progressive loss of neurons. In order to map brain functions, non-invasive neuroimaging 
techniques have been available for almost 80 years. Since different techniques have different 
shortcomings, the development and implementation of new functional imaging techniques 
have been complementary over these years (for review see Lulé et al., 2009). 
Electroencephalography (EEG), already developed in the 1920s by Hans Berger, is a 
technique for directly measuring electrical activity of cortical neurons on the surface of the 
head, thus providing a high temporal but a very low spatial resolution (Berger, 1929). In 
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1968, the first measurements of the magnetic equivalents of EEG recordings (electrical 
activity of cortical neurons induce magnetic fields) signalled the beginning of magneto 
encephalography (MEG), which complemented the field of non-invasive imaging of 
neuronal activity in the brain (Cohen, 1968). However, the interpretation of signals in the 
spatial domain remains challenging and is not suitable for subcortical structures.  
Since the mid 1970s, methods for measuring brain metabolism have been established. 
Changes in metabolism in the brain are a consequence of energy expenditure following 
neuronal activity in the brain. These data facilitate indirect measurement of overall brain 
activity. Accordingly, measurements of metabolism have improved spatial resolution 
especially for subcortical structures. Positron Emission Tomography (PET) and Single 
Photon Emission Computed Tomography (SPECT) record the dynamic distribution in the 
human brain of isotopes administered to a subject when assigned to a specific task (Phelps 
et al., 1975; Ter-Pogossian et al., 1975). Since metabolism is a second order effect following 
the electrical activity of neurons with latency, the temporal resolution of such measurements 
is low. Furthermore, radioactive substances have to be applied, limiting the application for 
scientific research.  
In the 1990s, functional MRI was developed. Functional MRI can be used to measure 
physiological changes not only of metabolism but also of e.g. blood flow in the brain. Like 
metabolism, blood flow is stimulated following oxygen expenditure of the cortical substrate. 
Like PET and SPECT, fMRI is a second-order signal with the problem of low temporal 
resolution but high spatial resolution, with the potential to indirectly measure cortical and 
subcortical activity easily during the performance of a given task. Accordingly, fMRI 
combines advantages of different non-invasive functional neuroimaging techniques. 
However, the indirect nature by which brain activity is currently measured by fMRI 
continues to limit its role as a “front-line” imaging tool.  
Notwithstanding, the clinical potential of a non-invasive probe of brain function with the 
option of repeated measures over time (e.g. due to a lack of radiation charge) in addition to 
the wide-spread availability of MRI scanners in many hospitals and research centres have 
extended its application in clinical science and contributed to an exponential increase in 
scientific publications on fMRI over the last decade (Jezzard & Buxton, 2006).  
4.2.1 Principles of fMRI  
Experimental work in animals first demonstrated that oxygenated blood and deoxygenated 
blood present different properties in a magnetic field, as noted by Linus Pauling as early as 
the 1930s (Pauling, 1936). Because of its unshielded iron, deoxygenated blood has 
paramagnetic properties whereas oxygenated blood has diamagnetic properties. 
Deoxyhaemoglobin as an endogenous paramagnetic contrast agent dephases nuclear spins 
of water protons in its vicinity with a physical effect of signal intensity change in T2*-
weighted MR images (Frahms et al., 1999). Ogawa and co-workers realised that those 
differences in magnetic properties in blood could have implications in the visualisation of 
local brain function (Ogawa et al., 1990a; 1990b).  
The most commonly used fMRI approach is to measure mainly blood flow changes using 
the blood-oxygenation-level-dependency (BOLD) effect (Kwong et al., 1992; Ogawa et al., 
1992), although other parameters can also be measured. A change in neuronal activity 
causes a decreased local blood oxygenation and an increased demand for oxygen. The local 
increase in deoxygenated blood level in the corresponding brain area is followed by a rise in 
cerebral blood flow that at least transiently ‘uncouples’ from oxygen consumption (Frahms 
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et al., 1992). The increase in blood flow and oxygenation decreases deoxyhaemoglobin 
concentration and leads to an increase in the corresponding MRI signal intensity and the 
effective spin-spin relaxation time T2*. This can be measured as a BOLD signal change in 
fMRI (Kim et al., 1997a; Logothetis et al., 2004; Ogawa et al., 1990b). 
The time curve of the measured BOLD signal in fMRI may be explained as follows: The local 
increase in deoxygenated blood level following neuronal activity in the corresponding brain 
area is assumed to be represented by the “initial dip” in the relevant BOLD signal. 
Oxygenated blood invades brain areas shortly after to compensate the increased metabolic 
rate in the neurons which results in a BOLD signal increase that peaks after around 6 s and 
returns to baseline after 20–30 s (Figure 1).  
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Fig. 1. Time series of BOLD response in fMRI. BOLD signal decreases as oxygen expenditure 
in the brain tissue (a: initial dip) increases; in the following phase extensive flow of 
oxygenated blood leads to increase in BOLD signal, reaching its maximum at about 6s (b). 
The signal returns to baseline within 20-30 s, often combined with a post-stimulus 
undershoot of the BOLD response (c). 
The BOLD in fMRI does not directly measure neural activity but relies on a surrogate 
‘secondary’ signal resulting from changes in oxygenation, perfusion (blood volume and 
flow), and metabolism (e.g. glucose and oxygen consumption) (Logothesis et al., 2004; Kim 
et al., 1997b; DiSalle et al., 1999). Neurovascular and metabolic correlates associated with 
brain activation are not yet fully understood, but there is evidence for a correlation between 
neuronal activity (or activation) in the brain and the fMRI signal (Logothesis et al., 2001). 
Functional MRI gives an approximation of neuronal activity, detecting, for example, task-
induced changes in local brain function (DiSalle et al., 1999; van Geuns et al., 1999). Because 
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the BOLD signal, however, derives from the interaction of multiple parameters (e.g. 
perfusion, metabolic turnover of neurons, density of venous vasculature of tissue, 
medication etc.) and may vary between brain areas and individuals as well as experimental 
and clinical settings, quantitative analysis in absolute terms is precluded (Kim et al., 1997a; 
Di Salle et al., 1999; Logothesis et al., 2001). 
MRI sequences that are best suited for functional neuroimaging should be both fast and 
sensitive to changes in the deoxyhaemoglobin concentration (Frahms et al., 1999). The MRI 
sequence that is generally considered to be the first choice for measuring BOLD in fMRI is a 
T2*-weighted echo-planar imaging (EPI) sequence, with its high speed yielding imaging 
times which translate into a maximum temporal resolution (Edelman et al., 1994; Kwong et 
al., 1995; Schmitt et al., 1998; Roberts et al., 2007). Temporal and spatial parameters of MRI 
scanning such as repetition time (TR) or slice thickness are limited by the T2* signal decay of 
the MRI sequence and determined according to study-specific factors, e.g. region of interest 
and field strength (Schmitt et al., 1998; Turner et al., 1998; Triantafyllou et al., 2005; Norris et 
al., 2006; Figure 2). Other MRI sequences such as fast low angle shot (FLASH) techniques 
facilitate access to higher spatial resolution at the expense of temporal resolution and 
volume coverage of larger volumes leading to higher scanning times (Frahms et al., 1999), 
which is not always favourable in clinical settings. 
 
 
Fig. 2. Example of orientation of EPI-sequence (white lines) along the anterior-posterior 
commissure overlaid onto a t1 weighted image (mprage) of a head (sagittal view) 
5. Functional neuroimaging in motor neuron diseases 
5.1 Functional neuroimaging of motor network 
In fMRI studies, ALS patients present higher volumes of activated brain areas in motor tasks 
compared with healthy controls, thus providing evidence for functional reorganisation and 
cortical plasticity in MND (Brooks et al., 2000; Lulé et al., 2009). Konrad et al. observed this 
in eleven ALS patients (Konrad et al., 2002) who performed a simple finger flexion task with 
10% of each individual´s maximum grip force. Increased activity was found in motor areas 
such as the premotor area, supplementary motor area, and the cerebellum. A similarly 
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increased activity in motor areas was observed in fifteen ALS patients compared to fifteen 
healthy controls during a sequential finger tapping movement task (Han et al., 2006) and in 
ALS patients compared both to patients with upper limb weakness due to peripheral nerve 
lesions and to controls during freely selected random joystick movements of the right hand 
(Stanton et al., 2007a). It has been proposed that these changes may represent cortical 
plasticity, as new synapses and pathways are developed to compensate for the selective loss 
of pyramidal cells in the motor cortex (Schoenfeld et al., 2005). A shift of activity to more 
anterior regions of the premotor cortex, i.e. Brodmann area (BA) 6, during upper limb 
movement has been observed in ALS patients (Konrad et al., 2002; Han et al., 2006), such 
findings being supported by previous functional imaging studies with PET (Kew et al., 
1993a; 1994). Furthermore, there is longitudinal fMRI evidence of progressive involvement 
of the premotor area in upper limb motor tasks in the course of the disease (Lulé et al., 
2007a). Thirteen patients with sporadic ALS and 14 healthy controls were asked to perform 
tasks involving a grip movement of the left, right, and both hands and to imagine the same 
without any overt movement of the hand. Motor imagery is known to involve similar areas 
as motor execution without being affected by confounding factors of effort and strain. In 
two consecutive fMRI measurements at a six-month interval, evidence for progressive 
recruitment of premotor areas in motor imagery was found in the course of the disease (Lulé 
et al., 2007a). 
Furthermore, a changed pattern and an anterior shift of activity in ALS were also observed 
in further cortical areas besides the premotor cortex for various motor tasks. For instance, 
increased involvement of supplementary motor areas (SMA) (Konrad et al., 2002; 2006; Han 
et al., 2006) and sensorimotor cortices has been seen (Brooks et al., 2000; Han et al., 2006; 
Stanton et al., 2007a; Mohammadi et al., 2011). Activity in contralateral sensorimotor cortex 
activity was increased the stronger the physical impairments were in patients (Mohammadi 
et al., 2011). Furthermore, activity in adjacent areas such as the bilateral inferior parietal lobe 
(BA 40) and bilateral superior temporal gyrus (BA 22) was increased in ALS patients 
compared to healthy controls during upper limb motor task performance in different fMRI 
studies (Stanton et al., 2007a). Altered somatotopy in the sensorimotor cortices was not 
observed in patients with exclusive lower motor neuron involvement (Kew et al., 1994), but 
only in ALS patients with clinical and functional involvement of both upper and lower 
motor neurons (Han et al., 2006; Kew et al., 1993a; 1994) or upper motor neuron only 
(Stanton et al., 2007a). This suggests that this changed pattern of activity might represent the 
loss of the pyramidal tract (Kew et al., 1994). A similar shift of activity in motor tasks into 
more anterior regions of sensorimotor and premotor areas and the SMA has been 
demonstrated for different neuropathologies with distinct aetiology such as stroke (Weiller 
et al., 2006). Thus, it may be assumed that this anterior shift represents a general pattern of 
plasticity as a response to neuronal loss in primary motor areas as a more or less efficient 
way to compensate motor function rather than an ALS-specific pattern of altered motor 
activation (Weiller et al., 2006). 
Increasing activity in ipsilateral cortical areas such as the sensorimotor cortex (Han et al., 
2006; Stanton et al., 2007a) and primary motor areas (Schoenfeld et al., 2005) has been 
observed in ALS patients. In a motor task of upper limb movement with varying task 
difficulty, six ALS patients presented an increased activity in ipsilateral primary motor areas 
compared to six healthy controls, corresponding to the degree of difficulty (Schoenfeld et al., 
2005). The fact that healthy controls recruit ipsilateral areas with increasing complexity of a 
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task suggests that ipsilateral involvement may reflect difficulty-dependent compensation 
and not a pathological pattern of activation per se. Accordingly, ALS patients may recruit 
existing neuronal pathways to compensate for functional loss in primary motor cortex 
(Schoenfeld et al., 2005). 
Furthermore, a more pronounced involvement of other motor functional areas at cortical and 
subcortical levels has been demonstrated in fMRI studies of motor tasks. For motor execution, a 
stronger involvement of areas involved in motor learning, such as the basal ganglia, cerebellum 
(Han et al., 2006; Konrad et al., 2006) and/or brainstem (Konrad et al., 2006) is evident. It may be 
assumed that alterations in functioning of basal ganglia are likely to be related to upper motor 
neuron pathology since they were observed in patients with exclusive upper motor neuron 
involvement (Tessitore et al., 2006). For motor imagery, a stronger recruitment of higher 
cognitive areas of motor control (frontal areas BA 9, 44, 45) and motor representation (inferior 
parietal activity, BA 40) in the course of the disease has been demonstrated in ALS patients 
compared to healthy controls (Lulé et al., 2007a). Overall, functional connectivity in the motor 
system network is altered in ALS (Mohammadi et al., 2009). 
Moreover, an increased involvement of extra motor areas, e.g. in the anterior cingulate 
cortex for movements of the right hand, is evident for patients with exclusive upper motor 
neuron involvement by fMRI (Tessitore et al., 2006). Similarly, an increased activity in 
anterior insular cortex and anterior cingulate cortex has been shown in other functional 
studies of motor execution (Brooks et al., 2000; Kew et al., 1993a; 1994).  
Whether the changed pattern of activity in other motor functional areas and higher 
cognitive areas during motor tasks represents the recruitment of redundant parallel motor 
system pathways or whether they map functional compensation or reorganisation can only 
be speculated upon. There is evidence that the change in cortical functioning of other motor 
and extramotor systems is primarily related to upper motor neuron pathology (Tessitore et 
al., 2006). 
For motor imagery, which is known to involve similar areas as motor execution, a different 
pattern of cortical activity is seen in ALS compared to motor tasks. In a movement imagery 
task of the right hand in 16 ALS patients, there was reduced BOLD activity in the left 
anterior parietal lobe, the anterior cingulate, and medial pre-frontal cortex compared to 17 
healthy controls (Stanton et al., 2007b). Reduced BOLD activity in the anterior cingulate 
cortex was also evident in a movement imagery task of both hands in the study by Lulé et al. 
(2007a). This reduction in cortical activation during motor imagery is at odds with the 
pattern observed during motor execution. This may represent the disruption of normal 
motor imagery networks by ALS pathology outside the primary motor cortex (Lulé et al., 
2007a; Stanton et al., 2007b). 
In summary, these data suggest an additional recruitment in brains of patients with ALS 
comprising bilateral areas in the premotor cortex in early stages along with involvement of 
higher order motor processing areas, determined by motor impairments (especially 
associated with upper motor neuron pathology) in the long run. This additional recruitment 
might be a (futile) way to compensate ALS-associated progressive functional loss.  
The cardinal feature of ALS is the loss of giant pyramidal Betz cells in the primary motor 
cortex (Brownell et al., 1970). It is nowadays assumed, however, that degeneration extends 
beyond the motor cortex. Neurodegeneration in motor areas might lead to progressive 
compensation of secondary motor areas for movement representation. Compensation 
terminates in a non-functional distributed cortical and subcortical ALS-specific motor 
network. More research needs to be done on how well the ALS patients in advanced stages 
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of the disease retain the potential for compensatory activity and how training of e.g. 
movement imagery might slow down the “compensatory” process. Functional MRI seems to 
be an appropriate way to gain more knowledge on this issue. 
5.2 Functional imaging of extramotor paradigms in MND 
The multisystemic character of ALS has been supported by various findings of functional 
imaging studies, although there are few fMRI studies. Involvement of sensory pathways in 
ALS has been reported by histopathological (Isaacs et al., 2007) and electrophysiological 
studies (Mai et al., 1998; Pugdahl et al., 2007). Evidence from fMRI studies for changed 
cortical patterns for sensory processing suggests the involvement of sensory processing 
areas in ALS (Lulé et al., 2010). In a visual, auditory and somatosensory stimulus paradigm, 
ALS patients presented reduced activity in primary and secondary sensory areas and an 
increased activity in higher associative areas. This increase in activity was correlated with 
loss of movement ability: The higher the physical restrictions were, the higher was the 
activity in those areas of third order sensory processing in ALS patients (Figure 3).  
 
 
Fig. 3. Changes in brain activity associated with loss of physical function in amyotrophic 
lateral sclerosis (ALS). Statistical maps presenting significantly increased and decreased 
blood oxygen level dependent activity associated with loss of physical function (measured 
with ALS functional rating scale, ALS-FRS) in ALS patients for visual, auditory and 
somatosensory stimulation. Areas with increasing (upper row, red) and decreasing (lower 
row, green) activity are shown. Significant activations are overlaid onto an axial (top row) 
and sagittal (bottom row) mean anatomical image of all subjects. Displayed are clusters >5 
voxels with uncorrected threshold p<0.001. P, posterior; R, right. 
Structural analysis of white matter integrity in this study measured with DTI provided 
evidence for a disruption of sensory nerve fibres in those ALS patients (Lulé et al., 2010). 
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Auditory processing underlying stimulus detection measured by MEG and subsequent 
memory-based comparison processes were abnormal in ten ALS patients with bulbar signs 
(Pekkonen et al., 2004), and a reduced response to auditory and visual stimuli was observed 
in ALS patients compared to healthy controls using EEG (Münte et al., 1998; Vieregge et al., 
1999). This finding may indicate a changed sensory processing capacity as well as reduced 
attention capacity (Pinkhardt et al., 2008), an ability assigned to the frontal cortex known to 
be involved in ALS (Ludolph et al., 1992; Kew et al., 1993b).  
The association of functional cortical changes and cognitive deficits has been confirmed by 
an fMRI paradigm of letter fluency and confrontation naming in 28 non-demented ALS 
patients compared to 18 healthy controls (Abrahams et al., 2004) and had been 
demonstrated previously by other functional imaging techniques (Ludolph et al., 1992; Kew 
et al., 1993b; Abrahams et al., 2004). There is increasing evidence that not only do 2–5% of 
ALS patients present an ALS/dementia complex but also that patients with classical ALS 
without obvious clinical evidence of cognitive deficits may have subtle changes in frontal 
cortical function (Ludolph et al., 1992; Kew et al., 1993b; Lulé et al., 2005; Lomen-Hoerth et 
al., 2002). The cognitive impairment has been reported as more pronounced in ALS patients 
with a bulbar onset compared to patients with spinal onset (Abrahams et al., 1997; Strong et 
al., 1999; Lomen-Hoerth et al., 2002; Schreiber et al., 2005) and is also evident in patients 
with primary lateral sclerosis (PLS; Piquard et al., 2006). Longitudinal investigation of ALS 
patients (up to 18 months) revealed that cognitive dysfunction in ALS occurred early in the 
disease course and that the cognitive deficits may not progress in synchrony with motor 
decline, but distinctly more slowly (Schreiber et al., 2005). Functional imaging studies 
confirm hypoperfusion in the resting state in the frontal cortex in ALS with or without 
cognitive deficits (Ludolph et al., 1992; Anzai et al., 1990; Tanaka et al., 1993). Apart from the 
local hypometabolism, there is also evidence for decreased activity in different cortical areas 
during the performance of different tasks. Findings from fMRI studies support the 
association of reduced frontal executive function and reduced activity in fronto-parietal 
areas, and confirm findings from studies using other imaging techniques (Kew et al., 1993b; 
Abrahams et al., 1996). In non-demented ALS patients, a correlation between reduced verbal 
fluency and reduced activity in middle and inferior frontal gyrus, anterior cingulate cortex, 
and parietal and temporal lobe have been observed in an fMRI study by Abrahams et al. 
which included 22 non-demented ALS patients compared with 18 healthy controls 
(Abrahams et al., 2004). There is no evidence of additional recruitment in other areas to 
compensate the functional loss in the frontal cortex, as has been shown for the motor 
system. Cognitive functions of frontal areas do not exhibit redundancy of motor pathways, 
and compensation is therefore not possible. Further longitudinal fMRI studies of different 
cognitive functions in ALS might improve our understanding of subclinical cognitive 
deficits in ALS.  
Further differences in cortical pattern activation were observed in ALS patients without 
significant cognitive impairments during processing of socio-emotional stimuli. Pictures of 
persons in emotional situations were presented to 13 ALS patients and 15 healthy controls at 
an initial measurement and to 10 of these ALS patients and 14 healthy controls at a second 
measurement after six months. ALS patients presented an increased activity in the right-
sided supramarginal area (BA 40), which is part of the social-information processing 
network. This difference in social-information processing pattern increased over the course 
of six months (Lulé et al., 2007b). The increased activity in the social information-processing 
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pathway might represent an altered sensitivity to social-emotional cues in ALS patients 
without cognitive deficits (Lulé et al., 2007b). Reduced activity in right sided frontal areas 
during processing of aversive emotional stimuli in ALS patients compared to controls 
support the assumption of an impaired processing pathway in ALS (Palmieri et al., 2010). 
More research is required to determine how successful and stable this compensatory 
recruitment is and again fMRI may be an important step. 
6. Functional neuroimaging in other neurodegenerative diseases like 
dementia, Parkinson’s disease, and Huntington’s disease 
6.1 Functional neuroimaging in dementia 
There is the described overlap of dementia and motor neuron diseases, however, contrary to 
the above described prominent role in MND, the role of imaging in dementia has 
traditionally been directed at ruling out treatable and reversible aetiologies (Tartaglia et al., 
2011). Contrary to motor neuron diseases it was rarely used to better understand the 
pathophysiology of the different dementias. 
Structural CT and MRI scans are mainly used to assess volumetric changes in dementias 
with decreases in gyral and increases in sulcal size secondary to decrease in synaptic 
density, neuronal loss, and cell shrinkage (Tartaglia et al., 2010). The medial temporal lobes, 
especially the hippocampus and entorhinal cortex (ERC), are among the earliest sites of 
pathologic involvement in AD (Braak & Braak, 1991), and studies have repeatedly shown 
decreased hippocampal and ERC volumes in patients with AD compared with age-matched 
controls (Appel et al., 2009). Other severely affected areas include the lateral parietal and 
posterior superior temporal regions and medial posterior portion of the cingulate gyrus 
(Jones et al., 2006), but atrophy is also evident in the frontal, temporal, and occipital lobes 
(Rusinek et al., 1991). Recent neuropathological data provide evidence that disease 
pathology starts in locus coeruleus and propagates into transentorhinal region and other 
cerebral regions (Braak & Del Tredici, 2011a). MRI of hippocampal and cortical regions in 
the parietal and lateral temporal regions has been successfully used as prognostic marker in 
patients with mild cognitive impairment (MCI) to develop AD (Du et al., 2003; Schott et al., 
2003). High field MRI provided evidence for a sensitivity of the thickness of CA1 to 
distinguish subjects with AD from normal controls (Kerchner et al., 2010). Like in ALS, 
white matter (WM) pathology was long not in focus of research. However, recent work 
provides evidence for WM changes in AD and MCI in association with cognitive changes 
(Zhang et al., 2007; Sexton et al., 2010). It might even be useful to distinguish different forms 
of dementia (Firbank et al., 2007; Zhang et al., 2009). NAA spectroscopy has been used as a 
possible diagnostic marker in dementia. NAA is consistently reported as being lower in the 
parietal gray matter and hippocampus of patients with AD than in cognitively normal 
elderly subjects (Schuff et al., 2002). 
On the functional level of the brain, evidence for a reduced function of frontal areas in FTD 
compared to AD was seen using fMRI (Rombouts et al., 2003). Furthermore, alterations in 
the default mode network (areas active during rest and idling of the brain) in resting state 
have been found for AD and MCI patients (Tartaglia et al., 2011). In the future, the 
application of neuroimaging in dementia will increase, as there will be extended evidence 
for prognostic and clinical marker for different forms of dementia. 
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6.2 Functional neuroimaging in Parkinson’s disease 
Like in most neurodegenerative diseases, neuroimaging in Parkinson’s disease has been 
challenging because the majorities of neurons are affected before clinical symptoms 
evolve and diagnosis is made. The clinical symptoms of PD appear when approximately 
50-80% of the nigral dopamine (DA) neurons have been lost already. Consequently, 
structural imaging has in general been unrewarding, although some newer MRI 
techniques, such as diffusion tensor imaging or shape analysis, are somewhat more 
promising and provided evidence for a reduced volume and changed connectivity of 
substantia nigra (Stössl, 2011). Functional neuroimaging is a promising candidate to 
detect specific changes in PD. Functional connectivity measured with resting state MRI 
provided evidence for changed pattern in motor network (Wu et al., 2009; Helmich et al., 
2010) and in the default network (Palmer et al., 2010). MRI spectroscopy may be useful in 
differentiating between PD and atypical parkinsonian syndromes (Firbank et al., 2002). 
Functional MRI in PD has been widely used and proven to be sensitive to e.g. 
polymorphism of catechol-O-metyltransferase (COMT) in PD. Different activation 
patterns in fronto-parietal areas in an fMRI task provided a clear link to genotype, 
dopaminergic medication and cognitive performance in PD patients (Williams-Gray et al., 
2007, 2008). In the future, functional neuroimaging may be used to get a fast and objective 
means of functional and genetic status in advanced stage PD patients. 
6.3 Functional neuroimaging in Huntington’s disease 
Among neurodegenerative disorders, HD is unique in that individuals destined to develop 
symptoms can be identified through genetic testing before clinical signs of the disease begin. 
This raises the possibility of developing therapies to prevent or delay the onset of clinical 
manifestations in HD gene carriers. Therefore, substantial effort has been dedicated to the 
characterization of quantitative descriptors of disease progression in premanifest 
individuals (Eidelberg & Surmeier, 2011). Neuroimaging may be used to clarify diagnosis in 
the pre-symptomatic stage. The idea of imaging as a preclinical marker in HD was 
supported by findings in a prospective observational study (Tabrizi et al., 2011). 
The vast number of neuroimaging studies in HD traditionally was on single brain regions 
like structural and functional studies on the striatum. Several PET studies revealed 
association of striatal and cortical dysfunction in association with genetic alterations and 
cognitive function. However, with the evolvement of MRI volumetric studies with low 
patient load, better insight on striatal function was found in a faster and easier way. 
However, even with this technique, systems-level changes might not be detectable. 
Connectivity studies like in resting state MRI might be more susceptible and applicable in 
the future. 
7. Conclusion 
Despite different aetiology of neurodegenerative diseases, similar approaches have been 
used in diseases of the central and peripheral nervous system. MRI based neuroimaging 
has extended our understanding of involvement of cortical structures which by far 
outreach the usually described clinical changes. Different neuroimaging techniques 
provide limitations that can be compensated by other techniques. Structural and 
functional MRI has taken over radio nucleotide dependent measurements in clinical 
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setting due to low patient load. Spectroscopy and resting state analysis will extend our 
understanding of molecular and functional changes of cortical structures and networks. 
MRI neuroimaging has the potential to fill the gap between pathogenesis and clinical 
outcome of neurodegenerative diseases. 
8. Future advances of neuroimaging in neurodegeneration 
8.1 Brain-computer interfaces 
Brain computer interfaces (BCIs) are a technique, which transfers and translates brain 
signals to technical devices for communication, control of environment (e.g. light switches) 
or prosthetic devices. BCIs are the only applicable means for communication in patients 
with advanced neurodegenerative diseases and no voluntary muscle control like in 
complete locked-in patients (CLIS) at end stage of ALS. There has been the unsolved 
question why patients in CLIS are unable to control EEG BCIs (Kübler & Birbaumer, 2008). 
With the means of functional neuroimaging, the question of activity of the idling brain of 
CLIS patients might be solved. Neuroimaging provide essential insight into the brains of 
patients with neurodegenerative diseases who are unable to communicate due to the loss of 
motor control like in ALS or cognitive ability like in dementia. 
8.2 Clinical implications 
MRI based neuroimaging has been extensively applied in diagnosis of neurodegenerative 
diseases. Low patient load and high applicability are in favour for this technique. 
Availability of MRI scanner in many clinics has already made neuroimaging an essential key 
in diagnosis of neurodegenerative diseases. The value of neuroimaging techniques for 
biomarker is still subject to ongoing debate; yet, there is a strong need for easy to apply 
biomarkers. In most neurodegenerative diseases, loss and death of motor neurons occur 
long before onset of clinical symptoms. Diagnosis is usually based on clinical symptoms 
when the majority of target cells are already affected. Braak and colleagues in Alzheimer’s 
disease have provided evidence for this. Tau tangles are found up to 30-50 years prior to 
onset of clinical symptoms (Braak & Braak, 1991; Braak & Del Tredici, 2011b). Effective 
therapeutic trials, however, ask for application as early as possible. Emergence of several 
disease-modifying drugs in neurodegenerative diseases has particularly highlighted the 
need for biomarkers of therapeutic response. Unwanted drug effects has brought additional 
requirement for effective biomarkers for optimal initial patient selection and timing of 
discontinuation (Turner et al., 2011). In the future, in search for robust biomarkes, MRI 
based neuroimaging techniques are a promising candidate. 
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